BMS-986012
- Generic Name
- BMS-986012
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1894272-37-7
- Unique Ingredient Identifier
- Q8PK97HY9B
- Background
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
- Associated Conditions
- -
- Associated Therapies
- -
Study of BMS-986012 in Subjects With Small Cell Lung Caner
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT02949895
- Locations
- 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan
Trial of BMS-986012 in Combination With Platinum and Etoposide
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT02815592
- Locations
- 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸Local Institution - 0004, Madrid, Spain
🇪🇸Local Institution - 0010, Malaga, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath